Impact of a Self-rehabilitation and Tele-rehabilitation Program on the Post-stroke Care Pathway

NCT ID: NCT06443840

Last Updated: 2024-06-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-06

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The AutonHome® clinical investigation, proposed by Dr Charles FATTAL (coordinator of this study), and carried out by the Association Approche (delegated promoter), aims to use the AutonHome® selfeducation device for the rehabilitation of patients who have suffered a Cerebrovascular Accident (CVA), and thus respond to the problems of therapeutic discontinuity highlighted today. Neuradom's AutonHome® device combines self-education and telecare. This device makes it possible to carry out personalised self-education programmes supervised by the therapist, enabling the therapeutic link with the patient to be maintained without the need for the patient to travel. This tool has already proved its usability and perceived usefulness in a previous clinical study, which demonstrated the feasibility of a self-education programme for hemiplegic patients, based on feedback. AutonHome® was considered by users to be a relevant, useful and safe complement to conventional rehabilitation.

On the basis of this feasibility study, the investigators wished to develop a second study around this AutonHome® device. In this second clinical investigation, in addition to perceived usefulness, the main objective is to demonstrate, in a population of stroke victims, that an experimental care pathway combining supervised self-education via AutonHome® with conventional re-education optimises the care pathway in terms of sensory-motor recovery, but also in terms of reduced length of stay and functional and medico-economic added value.

This clinical trial involves two parallel arms. Participants will be randomised into a control group, undergoing conventional in-centre rehabilitation, or into an experimental group, with self-rehabilitation and tele-rehabilitation in addition to conventional rehabilitation. The AutonHome study is a pilot study, with the aim of including 40 participants. Each centre will recruit 10 participants on a 1:1 randomisation basis, with 5 in the experimental group and 5 in the control group. Participants will be monitored for 15 weeks. This clinical investigation is multicentre, with 4 centres involved: the Centre Bouffard Vercelli (66962, Perpignan), the CMRRF de Kerpape (56275 Ploemeur), the association Saint-Hélier (35043, Rennes), and the Fondation ILDYS (29684 Roscoff).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhagic Unilateral Cortico-subcortical Hemispheric Stroke Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This protocol is carried out in accordance with the European Regulation 2017/745 on Medical Devices (MDR) and concerns a Class I medical device (MD) of category 4.2 (Article 82 MDR), corresponding to the CE marked MD used for its intended purpose without the objective of establishing conformity, and with an additional non-invasive and non-burdensome procedure.

This is a comparative, prospective, multicenter study (4 centers), controlled, randomized, open-label, with 2 parallel arms.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Participants will be randomised into a control group, undergoing conventional in-centre rehabilitation.

Group Type NO_INTERVENTION

No interventions assigned to this group

Experimental group

The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.

Group Type EXPERIMENTAL

AutonHome® device

Intervention Type DEVICE

The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AutonHome® device

The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who signed the written consent form to participate in the study after free and informed information
* Participants affiliated to a social security scheme (beneficiary or beneficiary) outside the AME.
* 18 years ≤ age ≤ 85 years,
* 1st recent ischemic or hemorrhagic unilateral cortico-subcortical hemispheric stroke
* Minimum post-stroke delay: 7 days
* Maximum post-stroke delay : 30 days
* SOFMER category 2: moderate strokes called category 2 according to SOFMER with an NIHSS (initial score of the National Institute of Health Stroke Scale) between 5 and 14 (Several deficiencies or motor deficit of the lower limb prohibiting walking, with recovery potential, a probable autonomy project (unilateral stroke).
* MoCA \> 23

Exclusion Criteria

* Participant deprived of liberty (by judicial or administrative decision)
* Adult participant subject to a legal protection measure or unable to express their consent
* Participation in another ongoing clinical trial
* Pregnant or breastfeeding women or women of childbearing age without effective contraception
* Lack of command of the oral and written French language
* Pre-existing neurological pathology
* Severe expression disorders (expression aphasia) affecting intelligibility
* Severe comprehension disorders (comprehension aphasia)
* Major cognitive disorders of the dementia or post-dementia type
* Unstable psychiatric disorders
* Unstabilized medical pathology
* Unbalanced epilepsy
* Color blindness
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société Neuradom

UNKNOWN

Sponsor Role collaborator

IMT Atlantique Brest

UNKNOWN

Sponsor Role collaborator

Association APPROCHE

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondation Ildys

Brest, Brittany Region, France

Site Status NOT_YET_RECRUITING

CMRRF de Kerpape

Ploemeur, Brittany Region, France

Site Status NOT_YET_RECRUITING

Association Saint-Hélier

Rennes, Brittany Region, France

Site Status NOT_YET_RECRUITING

Centre Bouffard Vercelli - USSAP

Perpignan, Pyrénées-Orientales, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie-Caroline Delebecque, CRA

Role: CONTACT

0297826174 ext. +33

Pauline Coignard, Doctor

Role: CONTACT

0297826060 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patricia Bourgogne, Doctor

Role: primary

0298293939 ext. +33

Thibaud Honore, Doctor

Role: primary

0297826060 ext. +33

Juliette Sainson, CRA

Role: backup

0297826293 ext. +33

Emilie Leblong, Doctor

Role: primary

0299295099 ext. +33

Linda Bodet, CRA

Role: backup

0299295043 ext. +33

Charles Fattal, Doctor

Role: primary

0430441100 ext. +33

References

Explore related publications, articles, or registry entries linked to this study.

RAOULT, Bérengère, PONTIER, Joanna, FICHEUX, Gilles and FATTAL, Charles, 2020. Étude de faisabilité d'un parcours d'auto-rééducation de patients hémiplégiques. Kinésithérapie Scientifique. Décembre 2020. No. 626, p. 5-13.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A01298-37

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Domiciliary VR Rehabilitation
NCT02699398 COMPLETED NA